India
· Delayed Price · Currency is INR Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 314.02 billion. The enterprise value is 299.34 billion.
| Market Cap | 314.02B |
| Enterprise Value | 299.34B |
Important Dates
The next estimated earnings date is Monday, November 4, 2024.
| Earnings Date | Nov 4, 2024 |
| Ex-Dividend Date | Aug 16, 2024 |
Share Statistics
Gland Pharma has 164.75 million shares outstanding. The number of shares has increased by 0.00% in one year.
| Shares Outstanding | 164.75M |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 37.24% |
| Float | 73.17M |
Valuation Ratios
The trailing PE ratio is 43.48 and the forward PE ratio is 32.51. Gland Pharma's PEG ratio is 1.60.
| PE Ratio | 43.48 |
| Forward PE | 32.51 |
| PS Ratio | 5.36 |
| PB Ratio | 3.60 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.60 |
Enterprise Valuation
| EV / Earnings | 41.45 |
| EV / Sales | 5.11 |
| EV / EBITDA | 22.57 |
| EV / EBIT | 32.11 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 4.27 |
| Debt / EBITDA | 0.28 |
| Debt / FCF | n/a |
| Interest Coverage | 34.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 6.83% |
| Revenue Per Employee | 13.92M |
| Profits Per Employee | 1.72M |
| Employee Count | 4,217 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.69% in the last 52 weeks. The beta is 0.33, so Gland Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +12.69% |
| 50-Day Moving Average | 1,954.99 |
| 200-Day Moving Average | 1,866.00 |
| Relative Strength Index (RSI) | 47.12 |
| Average Volume (20 Days) | 412,162 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 58.58 billion and earned 7.22 billion in profits. Earnings per share was 43.84.
| Revenue | 58.58B |
| Gross Profit | 33.47B |
| Operating Income | 9.32B |
| Pretax Income | 10.90B |
| Net Income | 7.22B |
| EBITDA | 13.26B |
| EBIT | 9.32B |
| Earnings Per Share (EPS) | 43.84 |
Balance Sheet
The company has 18.39 billion in cash and 3.72 billion in debt, giving a net cash position of 14.67 billion or 89.06 per share.
| Cash & Cash Equivalents | 18.39B |
| Total Debt | 3.72B |
| Net Cash | 14.67B |
| Net Cash Per Share | 89.06 |
| Equity (Book Value) | 87.24B |
| Book Value Per Share | 529.54 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 57.13%, with operating and profit margins of 15.92% and 12.33%.
| Gross Margin | 57.13% |
| Operating Margin | 15.92% |
| Pretax Margin | 18.60% |
| Profit Margin | 12.33% |
| EBITDA Margin | 22.64% |
| EBIT Margin | 15.92% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 1.05%.
| Dividend Per Share | 20.00 |
| Dividend Yield | 1.05% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.00% |
| Shareholder Yield | 1.05% |
| Earnings Yield | 2.30% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |